The Wellness, Longevity Consumer: Researching Singapore's Optimisation Boom
I watched a friend read his own blood work over brunch last month, scrolling a dashboard of biomarkers between mouthfuls of kaya toast the way other people check football scores. His triglycerides were down. Nobody at the table thought it odd (two of them asked for the clinic's name before the coffee came). Reading your own biology before lunch has become an ordinary Singaporean thing to do.
Here is the number that frames it. Singapore's wellness economy was worth about US$20.4 billion in 2023, roughly 35 percent larger than before the pandemic, and growing near 7.8 percent a year, the tenth-fastest rate in the world, according to the Global Wellness Institute. I checked that ranking twice, because it sits oddly beside what else is happening here. The government is making prevention nearly free. Healthier SG, the national preventive-health scheme, has signed more than 700,000 residents to a family doctor and a subsidised Health Plan. So one Singapore is handed prevention by the state, another pays for a private version, and the optimisation consumer lives in the gap between, still unmapped.
The Singapore that pays for prevention it could get for less
Start with the backdrop. Singapore has spent three years turning prevention into policy. Under Healthier SG, more than 1,000 GPs now enrol residents into long-term Health Plans built around screening and vaccination, not treatment after the fact, per the Ministry of Health. Participation in the Health Promotion Board's activity programmes passed 449,000 in 2023 (up 12 percent in a year). The message has landed. Prevention is no longer a nag, it is the national mood.
Then look at who is ageing into that mood. The share of citizens aged 65 and above has climbed from 13.1 percent in 2015 to 20.7 percent in 2025, heading for one in four by 2030, according to the National Population and Talent Division. A population that lives long starts caring about the quality of the extra years, not just the count. So why pay a premium for prevention the state already hands out? Because the free version is population-scale and once a year, and this buyer wants it personal, granular, and now. The state teaches prevention, the demography sharpens the stakes, and a slice of the public treats the national baseline as a floor, not a ceiling. That slice, I think, is worth mapping.
A boom built on measurement, not medicine
The private market that grew next to the public one does not behave like medicine. It behaves like measurement. At Camden Medical Centre, Chi Longevity opened in 2023 as what it calls Singapore's first evidence-based longevity clinic, founded by physician-scientist Andrea Maier. On Robinson Road, NOVI Health runs longevity and metabolic programmes off more than a hundred tracked biomarkers. Newer names keep arriving: Eternami launched in 2025, and Morrow, a 38,000-square-foot hub backed by a reported S$200 million, opened at the end of that year, as The Peak documented in its account of the longevity race.
The menu underneath keeps getting longer. Biomarker blood panels, epigenetic clocks that estimate a biological age, DEXA scans, full-body MRIs, VO2 max tests, sleep-tracking rings, cold-plunge and contrast therapy, red-light panels. Tatler catalogued the same stack in its report on the biohacking boom and priced the entry ticket honestly (a decent blood panel runs around $600). Serious clinical screening, or theatre with a heart-rate monitor attached? Most consumers cannot tell which at the point of sale, and that is exactly why the research question matters.
Three optimisation consumers, not one market
The first mistake is to treat "the wellness consumer" as one person with one motive. Run enough interviews and the buyers split, not by age or income but by the belief that gets them to pay. Let me call them the Quantifier, the Hedger, and the Feel-Now Buyer, holding the names loosely (the motives are steadier than my labels for them).
The Three Optimisation Consumers
The Quantifier
Believes what gets measured gets managed. Buys biomarker panels, wearables, and VO2 max tests, and treats the number moving the right way as the product itself.
Reorders the panel each quarter to watch the trend lineThe Hedger
Has watched a parent decline and treats prevention as insurance. Buys screening and supplements as a premium against a feared future, weighed against the cost of the disease.
Full-body MRI to be sure, then the daily supplement stackThe Feel-Now Buyer
Wants energy, sleep, and recovery this week, not a longer life in theory. Buys sleep tech and cold plunge for how Monday morning feels, and drops anything that does not deliver.
Keeps the contrast-therapy class and the sleep ring, cancels the restSo which belief is buying? These three types live inside one person and swap by category, which is what makes a clean segment impossible. The same 45-year-old is a Quantifier about his blood work, a Feel-Now Buyer about his sleep, and a flat refuser about cold water, all in one week (I have watched that switch inside a single ninety-minute interview). What holds steady is the logic under each purchase. Each type asks a different question when the card comes out, and none of them is "is there a randomised trial for this." Actually, that is not quite right. The Hedger reads the trials closely, but even she is really asking whether this keeps her out of the hospital bed she watched her father lie in.
What they say and what they actually buy
This is where surveys fail hardest. Optimisation spending carries a faint social embarrassment in Singapore, a sense that caring this much about your body is a little atas (to borrow the word they use), so the stated position runs cooler than the behaviour. Ask directly and the answer is a shrug. Watch the spending and the truth turns up. We map that divergence in every study we run, the same problem I wrote about in why consumer research in Singapore misleads. Here is its shape across the categories that make up the boom.
| Category | What they say | What they actually do |
|---|---|---|
| Supplements | "I don't really believe in supplements" | Keeps a $200-a-month stack and quietly reorders the ones they can feel |
| Biomarker testing | "It is a bit much, just clever marketing" | Booked the $600 panel and screenshots the results to compare with friends |
| Sleep tech | "I sleep fine, I don't need a gadget" | Wears the ring nightly and checks the score before the first coffee |
| Cold plunge and recovery | "That is for the influencer crowd" | Pays for the contrast-therapy membership and posts nothing about it |
| Longevity clinic | "I would never pay those prices" | Did the first consult to see the numbers, then rebooked for the follow-up |
The supplements row is the tell. Almost nobody admits to believing in them, and almost everybody keeps a drawer. The gap has an economic edge too. When Mito Health offers members a blood panel at around $15 against as much as $300 at a hospital lab, it is not selling a cheaper test so much as removing the last excuse a Hedger had for not knowing. Price the friction out and the resistance collapses, the most useful thing to understand about this buyer.
The conviction ladder that explains the spend
You might expect marketing to move this market. In my experience it barely does. This buyer sits at one of three points, and only one of them is a claim on a website. Where they sit depends on the strongest evidence they have seen with their own eyes, or so the interviews suggest.
The Conviction Ladder
The right-hand point is where the money and the loyalty sit. A consumer who ignores every longevity advertisement will pay again and again once she has watched one of her own markers improve, because now the proof is her own body, which she trusts more than any study. This is why measurement, not medicine, is the engine. The number is the hook, the retention tool, and the referral. It also, and this is the uncomfortable part, works just as well when the treatment does very little (a moving biomarker feels like progress whether or not it adds a single year). Conviction and efficacy are not the same axis, and the category has learned to sell the first.
Where the boom quietly over-promises
So where does this tip into over-promising? Three places, worth naming because a brand that avoids them earns the trust the others are burning. The first is the biological-age number. An epigenetic clock that reports a "biological age" of 38 sells beautifully and rests on softer science than that single confident figure admits. The second is the supplement stack sold as a substitute rather than an add-on, when the evidence keeps pointing back to dull fundamentals (nutrition, exercise, sleep, stress, social connection, the things nobody can charge a premium for). As one clinician told The Peak, health span is not extended by a single pill or protocol. The third is the leap from a data point to an outcome. Tatler's reporting on the same clinics quoted the worry plainly, that too many protocols run on snapshots of data with no real outcomes behind them.
I want to be careful here, because the reflex is to dismiss the whole category as snake oil, and that is wrong too. Actually, let me put it more precisely. The clinical screening underneath is often genuinely useful, and catching a metabolic problem at 45 is worth real money. The over-promising sits in the packaging (the language of reversal and biological youth wrapped around what is really careful screening and lifestyle advice). Brands that research where that line falls will outlast the ones selling a light show. It is the same trust pattern I have seen in chronic disease management, where patients walk away from anything that over-claims, and in mental health services research, where the gap between promise and result decides whether anyone comes back.
How you actually research the optimisation consumer
The method question I get is a version of "can you separate what these people believe from what they are performing?" It can be done, but not with a survey and a rating scale, exactly where the cool, socially acceptable answer lives. The workhorse is the one-on-one in-depth interview, run in the person's home where the evidence sits. Ask to see the supplement drawer, which apps fill the first screen of the phone, the dashboard, and the last number that made them book something. Behaviour told over the real objects beats any attitude captured on a scale.
Focus groups earn their place at the social end, where the codes around indulgence and atas spending surface, though I watch the room carefully (a group of Singaporeans will perform scepticism at each other and talk themselves cooler than any of them privately is). Mobile ethnography has become my quiet preference for this buyer, a photo diary that catches the 6am cold plunge, the second supplement order, the small spends that never survive an interview a week later. The same instinct runs through service audits of the studios and clinics themselves, the ground our fitness and wellness mystery shopping covers.
Recruitment is the part that goes wrong most. Screen only the true believers and the study makes the category look bulletproof. Screen only the sceptics and it looks like a bubble about to pop. Both belong in the sample. No, all three do, the believers, the sceptics, and the awkward middle (the curious-but-embarrassed buyer who is the real centre of gravity). This segment overlaps hard with the wealthier end of the market, and much of what we have learned about how affluent Singaporeans really decide, rather than how they narrate it afterwards, carries straight across.
What this means for brands
So what changes on Monday? A brand that researches only its own happy customers is studying the Quantifiers and missing everyone still hesitating at the edge. Recruit the sceptics and the embarrassed too. Price deliberately against each belief, because the Quantifier pays for the data, the Hedger for reassurance, and the Feel-Now Buyer for Tuesday morning (three different products, even when they share a lobby). Test claims the way a suspicious buyer does, with a friend first and then with her own body, before she believes a word of the marketing.
The larger move is to stop filing this under lifestyle and start treating it as demand, which is why we run it inside our healthcare market research practice, next to the patient and adherence work, not off in a corner. It sits close to the silver economy consumer too, the same instinct to spend on more good years, arriving a decade earlier. Fold the optimisation buyer into the demand map you already keep for everyone else, the kind we build in the Singapore Consumer Intelligence Matrix, and the category stops looking like a fad and starts looking like a durable, high-margin segment that simply arrived early.
The market hiding behind a shrug
The story Singapore usually tells about wellness is a sceptical one, all snake oil and rich men freezing themselves for fun. Some of that is fair. It also misses the size of what is happening. The same city that made prevention a public good has grown a private market willing to pay ten or a hundred times the subsidised price for a more personal version of the same idea, a market still researched, when it is researched at all, as a punchline.
At least, that is my current reading, and I expect the segments to keep drifting as the science firms up and the theatre gets found out. What I am confident about is the correction. Stop asking Singaporeans whether they believe in longevity, because they will shrug and say no. Watch what they actually buy, in their own homes and languages, and this buyer stops looking like a caricature and starts looking like one of the most committed, least understood buyers in the market.
What brands ask us about Singapore's wellness consumers
How big is Singapore's wellness and longevity market?
Who is the health optimisation consumer in Singapore?
Why do surveys underestimate wellness spending?
What convinces the longevity consumer to buy?
Where is the longevity category over-promising?
Researching who actually buys longevity, and what they will pay for
The optimisation consumer says one thing on a survey and spends another way in private. We design in-depth interviews, focus groups, and mobile ethnography that reach wellness and longevity buyers in their own homes and languages, separate genuine conviction from performed scepticism, and show you where your claims earn trust and where they quietly burn it.
Request a quote →
